Đang chuẩn bị liên kết để tải về tài liệu:
IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: A case report

Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). |